Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation

The divergent views on lung cancer treatments in fibrosing lung patients reflect differences due to variable side-effect incidences in different countries and among ethnicities. International efforts are needed to better define treatment approaches. https://bit.ly/3DX40fq

Detalles Bibliográficos
Autores principales: Funke-Chambour, Manuela, Kewalramani, Namrata, Machahua, Carlos, Poletti, Venerino, Wells, Athol U., Cadranel, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835994/
https://www.ncbi.nlm.nih.gov/pubmed/36655227
http://dx.doi.org/10.1183/23120541.00469-2022
_version_ 1784868775077609472
author Funke-Chambour, Manuela
Kewalramani, Namrata
Machahua, Carlos
Poletti, Venerino
Wells, Athol U.
Cadranel, Jacques
author_facet Funke-Chambour, Manuela
Kewalramani, Namrata
Machahua, Carlos
Poletti, Venerino
Wells, Athol U.
Cadranel, Jacques
author_sort Funke-Chambour, Manuela
collection PubMed
description The divergent views on lung cancer treatments in fibrosing lung patients reflect differences due to variable side-effect incidences in different countries and among ethnicities. International efforts are needed to better define treatment approaches. https://bit.ly/3DX40fq
format Online
Article
Text
id pubmed-9835994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-98359942023-01-17 Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation Funke-Chambour, Manuela Kewalramani, Namrata Machahua, Carlos Poletti, Venerino Wells, Athol U. Cadranel, Jacques ERJ Open Res Correspondence The divergent views on lung cancer treatments in fibrosing lung patients reflect differences due to variable side-effect incidences in different countries and among ethnicities. International efforts are needed to better define treatment approaches. https://bit.ly/3DX40fq European Respiratory Society 2022-12-12 /pmc/articles/PMC9835994/ /pubmed/36655227 http://dx.doi.org/10.1183/23120541.00469-2022 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Correspondence
Funke-Chambour, Manuela
Kewalramani, Namrata
Machahua, Carlos
Poletti, Venerino
Wells, Athol U.
Cadranel, Jacques
Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_full Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_fullStr Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_full_unstemmed Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_short Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
title_sort reply to: pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835994/
https://www.ncbi.nlm.nih.gov/pubmed/36655227
http://dx.doi.org/10.1183/23120541.00469-2022
work_keys_str_mv AT funkechambourmanuela replytopharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT kewalramaninamrata replytopharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT machahuacarlos replytopharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT polettivenerino replytopharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT wellsatholu replytopharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation
AT cadraneljacques replytopharmacotherapyforlungcancerwithcomorbidinterstitialpneumonialimitedevidencerequiresappropriateevaluation

Ejemplares similares